Position in CELC
as of Mar 31, 2026
· filed May 15, 2026
Position Value
$8,050,979
+$7,556,979 QoQ
Shares Held
70,536
+605.4% QoQ
Ownership
0.145%
of shares outstanding
% of Portfolio
0.07%
of 13F equity value
Holder Rank
—
not a current holder
Holding Since
Sep 2025
2 quarters on record
Voting authority
Sole 100.ToString("F0")%
Shared 0.ToString("F0")%
None 0.ToString("F0")%
Common Shares in CELC Over Time
Shares Held
Position Value (USD)
Position in Biotechnology
Healthcare · as of Mar 31, 2026Freestone Grove Partners LP holds $288,180,842 across 51 Biotechnology names. CELC ranks #11 (2.8% of the industry book) .
| # | Ticker | Company | Shares | Value (USD) | Open |
|---|---|---|---|---|---|
| 1 | TECH |
BIO-TECHNE Corp
|
820,072 | $42,856,962 | |
| 2 | BMRN |
Biomarin Pharmaceutical Inc
|
606,187 | $34,243,503 | |
| 3 | RPRX |
Royalty Pharma plc
|
616,377 | $29,567,604 | |
| 4 | REGN |
Regeneron Pharmaceuticals, Inc.
|
30,625 | $23,662,100 | |
| 5 | DNTH |
Dianthus Therapeutics, Inc. /DE/
|
239,943 | $20,136,016 | |
| 6 | KALV |
KalVista Pharmaceuticals, Inc.
|
882,906 | $17,772,897 | |
| 7 | CYTK |
Cytokinetics Inc
|
216,769 | $14,287,244 | |
| 8 | PCVX |
Vaxcyte, Inc.
|
224,731 | $13,059,118 |
All Filings in CELC
Export CSV
2 filing rows on record
| Report Date | Value (USD) | Shares | Type | Discretion | Filed | |
|---|---|---|---|---|---|---|
| 2026-03-31 | $8,050,979 | 70,536 | Shares | Sole | 2026-05-15 | |
| 2025-09-30 | $494,000 | 10,000 | Shares | Sole | 2025-11-14 | |
| No filing history on record for this holder in this stock. | ||||||